Aurinia Q2 2021 revenue $6.6M, 415 LUPKYNIS PSFs, guides FY revenue $40-50M

Aurinia Pharmaceuticals Inc.

2021-Q2 EPS reported -$0.76 revenue$7,534,000

Net revenue $6.6M (624% growth over Q1 2021); net loss $47.0M ($0.37/share) vs $26.5M loss in Q2 2020.
Received 415 LUPKYNIS patient start forms in Q2, over 800 YTD; >50% converted to therapy.
Cash and investments $323.7M; 2021 LUPKYNIS net revenue guidance $40-50M.
Otsuka filed MAA in EU for voclosporin; Aurinia eligible for up to $30M milestones plus royalties.
Appointed Dr. Brinda Balakrishnan to Board; Lancet published AURORA-1 results.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.